Axio BioPharma and The Bioforge team up on AI biomanufacturing data access

Axio BioPharma and The Bioforge announced a partnership to connect Axio Lattice with BioOptima AI™ so biopharmaceutical companies can use historical process data for AI-driven optimization without moving ownership or centralizing data. The collaboration targets fragmented development and manufacturing records across sites, systems and partner organizations.

Why it matters: - Biopharmaceutical companies often sit on years of process data that is hard to reuse because it lives in different systems, uses different terminology and spans multiple sites. - The partnership is designed to help teams turn that fragmented knowledge into input for AI-supported process optimization without forcing a disruptive data migration. - The approach could matter most in sponsor-manufacturing partner relationships, where neither side wants to move raw process data into the other party’s system.

What happened: - Axio BioPharma and The Bioforge announced a strategic partnership on Aug. 10, 2026. - The companies plan to connect Axio Lattice with BioOptima AI™ to make historical process data more usable for future development and manufacturing decisions. - The planned workflow keeps underlying data in its original environment and under the control of its existing owner.

The details: - Axio Lattice is a vendor-neutral coordination and translation layer for biomanufacturing data. - BioOptima AI™ continuously learns from experimental and process data and recommends which experiment to run next. - BioOptima AI™ is designed to provide value from the first experiment, even for customers with limited or no historical data. - Axio Lattice is intended to make process information comparable across laboratory information management systems, manufacturing execution systems, electronic laboratory notebooks, historians, enterprise resource planning platforms and quality management systems. - The companies said the combined workflow would let BioOptima AI™ use context created by Lattice to guide experimental decisions while the data stays where it is stored. - The partnership plan includes coordinated workflows, proof-of-concept pilots, joint customer opportunities and co-branded technical and educational content. - The companies may also collaborate on case studies, application notes, performance benchmarks and presentations. - Axio BioPharma is headquartered in Madison, Wisconsin. - Axio BioPharma also operates Axio Forge, a high-throughput non-GMP antibody lab that produces research-grade monoclonal antibodies on a 3-5 week turnaround. - The Bioforge develops BioOptima AI™ as an adaptive AI platform for strain engineering, process development and scale-up.

Between the lines: - The partnership is a bet that AI tools work better when they can learn from more than newly generated experiments. - The companies are positioning data interoperability as an alternative to centralized repositories, which can trigger ownership, security and IT concerns. - The pitch is also about avoiding a common bottleneck in biomanufacturing: valuable process knowledge that exists, but cannot be easily compared or reused.

What's next: - Axio BioPharma and The Bioforge plan to explore proof-of-concept pilots and coordinated customer workflows. - The companies are also looking at case studies and technical content to show how connected historical data can support bioprocess development. - If the collaboration advances, the next step will be demonstrating that AI can optimize processes across organizations without moving the source data.

The bottom line: - The partnership aims to give biomanufacturers a way to use historical process knowledge for AI-driven optimization while keeping data ownership and storage unchanged.